Global Driver Analysis: The Rapid Evolution of the De-Identified Health Data Market

The growing application of healthcare data that protects patient identity is transforming medical research and patient care. As technology advances and healthcare providers seek safer ways to utilize data, the de-identified health data market is set for remarkable expansion. Let's explore its projected value, key players shaping the industry, current trends, and how the market is segmented.

Projected Market Value and Growth Trajectory of the De-Identified Health Data Market
The de-identified health data sector is anticipated to experience swift growth, reaching a valuation of $16.07 billion by 2030. This expansion reflects a compound annual growth rate (CAGR) of 11.7%. Factors propelling this growth include the increasing adoption of AI-driven health insights, higher investments in precision medicine research, the rise of value-based care analytics, growing demand for secure health data exchange, and the broader use of real-world evidence in regulatory processes. Key trends expected during this period involve the proliferation of large-scale de-identified data platforms, enhanced real-world evidence analytics, privacy-preserving data sharing techniques, expanded use of longitudinal patient data, and the integration of diverse healthcare data sources.

Download a free sample of the de-identified health data market report:
https://www.thebusinessresearchcompany.com/report/de-identified-health-data-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Organizations Steering the De-Identified Health Data Market
Several influential companies dominate this space, including UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., and Gradient Health Inc.

Expanding Real-World Evidence Capabilities Through Strategic Acquisitions
In July 2025, Datavant Inc., a US-based health information technology firm, acquired Aetion Inc., a move aimed at enhancing its real-world evidence (RWE) capabilities. This acquisition integrates Aetion's advanced analytics platform, enabling Datavant to offer life sciences and healthcare clients a comprehensive solution for generating regulatory-grade insights from de-identified health data. Aetion is recognized for its RWE platform, providing de-identified health data services such as Aetion Generate.

The growing application of healthcare data that protects patient identity is transforming medical research and patient care. As technology advances and healthcare providers seek safer ways to utilize data, the de-identified health data market is set for remarkable expansion. Let's explore its projected value, key players shaping the industry, current trends, and how the market is segmented.

Projected Market Value and Growth Trajectory of the De-Identified Health Data Market
The de-identified health data sector is anticipated to experience swift growth, reaching a valuation of $16.07 billion by 2030. This expansion reflects a compound annual growth rate (CAGR) of 11.7%. Factors propelling this growth include the increasing adoption of AI-driven health insights, higher investments in precision medicine research, the rise of value-based care analytics, growing demand for secure health data exchange, and the broader use of real-world evidence in regulatory processes. Key trends expected during this period involve the proliferation of large-scale de-identified data platforms, enhanced real-world evidence analytics, privacy-preserving data sharing techniques, expanded use of longitudinal patient data, and the integration of diverse healthcare data sources.

Download a free sample of the de-identified health data market report:
https://www.thebusinessresearchcompany.com/report/de-identified-health-data-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Organizations Steering the De-Identified Health Data Market
Several influential companies dominate this space, including UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., and Gradient Health Inc.

Expanding Real-World Evidence Capabilities Through Strategic Acquisitions
In July 2025, Datavant Inc., a US-based health information technology firm, acquired Aetion Inc., a move aimed at enhancing its real-world evidence (RWE) capabilities. This acquisition integrates Aetion's advanced analytics platform, enabling Datavant to offer life sciences and healthcare clients a comprehensive solution for generating regulatory-grade insights from de-identified health data. Aetion is recognized for its RWE platform, providing de-identified health data services such as Aetion Generate.

Innovations Shaping the Future of the De-Identified Health Data Market
Key companies in the fragile X syndrome (FXS) treatment market are pushing forward with innovative therapies, including calcium-activated potassium (BK) channel activators, which target neurological pathways to improve treatment outcomes. For example, in January 2025, Spinogenix Inc., a biotechnology research company based in the US, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SPG601, a BK channel activator aimed at treating fragile X syndrome. This designation accelerates clinical development and regulatory review, underlining the urgent need for effective therapies. SPG601 holds promise in improving cognitive and behavioral symptoms by addressing fundamental neurological dysfunctions.

Detailed Segmentation of the De-Identified Health Data Market
This market is categorized by several dimensions:

By Type:
- Clinical Data
- Genomic Data
- Patient Demographics
- Prescription Data
- Hospital and Provider Data
- Pharmacogenomic Data

By Application:
- Clinical Research and Trials
- Public Health
- Precision Medicine
- Health Economics and Outcomes Research (HEOR)
- Population Health Management
- Drug Discovery and Development
- Healthcare Quality Improvement
- Insurance Underwriting and Risk Assessment
- Other Applications

By End-User:
- Pharmaceutical Companies
- Biotechnology Firms
- Healthcare Providers
- Insurance Companies or Healthcare Payers
- Research Institutions
- Government Agencies
- Other End-Users

Further subcategories break down into:

Clinical Data includes electronic health records, medical imaging, lab test results, surgical and pathology reports, and vital signs measurements.
Genomic Data encompasses whole genome sequencing, exome sequencing, single nucleotide polymorphisms, gene expression profiles, and epigenetic data.
Patient Demographics cover age, gender, ethnicity, geographic location, socioeconomic status, and marital status.
Prescription Data involves medication orders, dosage details, refill history, drug allergies, and pharmacy records.
Hospital and Provider Data consists of provider performance metrics, care delivery outcomes, billing and claims data, and resource utilization.
Pharmacogenomic Data relates to gene-drug interaction data, adverse drug reaction information, personalized therapy responses, and variations in drug efficacy.

This comprehensive segmentation reflects the diverse and complex nature of the de-identified health data market, highlighting its critical role in advancing healthcare analytics and patient outcomes globally.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.